Education, Science, Technology, Innovation and Life
Open Access
Sign In

Advancements in Pharmacological Treatment of Pregnancy-Induced Hypertension

Download as PDF

DOI: 10.23977/medbm.2024.020107 | Downloads: 7 | Views: 189

Author(s)

Ximin Peng 1

Affiliation(s)

1 Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, Shanwei, China

Corresponding Author

Ximin Peng

ABSTRACT

Pregnancy-induced hypertension (PIH) is a common obstetric disease characterized by clinical symptoms such as proteinuria, hypertension, and edema. It may even lead to heart and kidney failure, posing a serious threat to the life safety of pregnant women and neonates. Therefore, it is imperative to enhance hemodynamic monitoring for pregnant women and provide personalized prevention and treatment strategies. Medication plays a crucial role in managing pregnancy-induced hypertension, with diuretics, antihypertensive agents, and antispasmodics being the primary pharmacological interventions to improve the condition. This research, validated through literature review, focuses on the progress in drug research related to pregnancy-induced hypertension, aiming to contribute new insights to the clinical diagnosis and treatment of PIH.

KEYWORDS

Pregnancy-induced hypertension; Drug treatment; Treatment progress

CITE THIS PAPER

Ximin Peng, Advancements in Pharmacological Treatment of Pregnancy-Induced Hypertension. MEDS Basic Medicine (2024) Vol. 2: 48-55. DOI: http://dx.doi.org/10.23977/medbm.2024.020107.

REFERENCES

[1] Zhang Yang, Yang Hui, Yang Liu, et al. Research status and prospects of metformin in hypertensive disease during pregnancy [J]. Chinese Journal of Obstetrics and Gynecology, 2020, 55(8):567-571.
[2] Liu Yufan, Min Hui, Xue Xiaorong, et al. Quality evaluation of evidence-based guidelines for drug intervention in hypertension during pregnancy [J]. Chinese Medicine, 2020, 15(1):109-113.
[3] Yu Yahui, Feng Xin. Current research status of pharmacogenomics in hypertensive diseases during pregnancy [J]. Chinese Journal of Clinical Pharmacology, 2020, 36(12):1726-1728, 1732.
[4] Garovic V D, Dechend R, Easterling T, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association[J]. Hypertension, 2022, 79(2): e21-e41.
[5] Moussa H N, Arian S E, Sibai B M. Management of hypertensive disorders in pregnancy[J]. Women’s health, 2014, 10(4): 385-404.
[6] Younes S T, Ryan M J. Pathophysiology of cerebral vascular dysfunction in pregnancy-induced hypertension[J]. Current Hypertension Reports, 2019, 21: 1-8.
[7] Khosla K, Heimberger S, Nieman K M, et al. Long-term cardiovascular disease risk in women after hypertensive disorders of pregnancy: recent advances in hypertension[J]. Hypertension, 2021, 78(4): 927-935.
[8] Cox A G, Marshall S A, Palmer K R, et al. Current and emerging pharmacotherapy for emergency management of preeclampsia [J]. Expert Opinion on Pharmacotherapy, 2019, 20(6): 701-712.
[9] Townsend R, O’Brien P, Khalil A. Current best practice in the management of hypertensive disorders in pregnancy[J]. Integrated blood pressure control, 2016: 79-94.
[10] Xiang X, Wang F, Zhao N, et al. Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo[J]. Cellular and Molecular Biology, 2020, 66(8): 9-13.
[11] Scantlebury D C, Schwartz G L, Acquah L A, et al. The treatment of hypertension during pregnancy: when should blood pressure medications be started?[J]. Current cardiology reports, 2013, 15: 1-10.
[12] Lindheimer M D, Taler S J, Cunningham F G. Hypertension in pregnancy[J]. Journal of the American society of Hypertension, 2010, 4(2): 68-78.
[13] Lewis R, Sibai B. Recent advances in the management of preeclampsia[J]. Journal of Maternal-Fetal Medicine, 1997, 6(1): 6-15.
[14] Togarikar S M. Efficacy of methyldopa versus nifedipine in mild and severe pregnancy induced hypertension[J]. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2017, 6(10): 4544-4549.
[15] Chang K J, Seow K M, Chen K H. Preeclampsia: Recent Advances in Predicting, Preventing, and Managing the Maternal and Fetal Life-Threatening Condition[J]. International Journal of Environmental Research and Public Health, 2023, 20(4): 2994.
[16] Kalsoom S, Majeed N, Riaz M, et al. Labetalol Versus Methyldopa: Comparison of Frequency of Small for Gestational Age in the Treatment of Pregnancy Induced Hypertension[J]. Journal of Rawalpindi Medical College, 2018.
[17] Frishman W H, Schlocker S J, Awad K, et al. Pathophysiology and medical management of systemic hypertension in pregnancy[J]. Cardiology in review, 2005, 13(6): 274-284.
[18] Aggarwal N, Negi N, Aggarwal A, et al. Pregnancy with portal hypertension[J]. Journal of clinical and experimental hepatology, 2014, 4(2): 163-171.
[19] Liu L, Yao C, Song Z. MicroRNA-195-5p Attenuates Pregnancy-Induced Hypertension by Inhibiting Oxidative Stress via OTX1/MAPK Signaling Pathway[J]. Biochemical Genetics, 2024: 1-16.
[20] Caia Z, Dong S, Zhang Y. The effect of dietary and nutritional intervention on pregnancy complications[C]//Third International Conference on Biological Engineering and Medical Science (ICBioMed2023). SPIE, 2024, 12924: 785-789.
[21] Doğan M E, Pota Ç E. Investigation of the effects of gestational diabetes and hypertension on retinal and choroidal microvascular circulation using swept-source optical coherence tomography angiography[J]. Microvascular Research, 2024, 152: 104622.
[22] Wu Hairong, Zhao Na. Effects of magnesium sulfate combined with labetalol in the treatment of gestational hypertension on homocysteine, fetal blood flow and pregnancy outcomes [J]. Chinese Journal of Clinicians, 2020, 48(2):220-223.
[23] Kumar C H, Roy S, Aishwarya T, et al. Pregnancy-induced hypertension: risk factors and current treatment strategies[J]. Cellular, Molecular and Biomedical Reports, 2023, 3(4): 197-204.
[24] Socha M W, Chmielewski J, Pietrus M, et al. Endogenous digitalis-like factors as a key molecule in the pathophysiology of pregnancy-induced hypertension and a potential therapeutic target in preeclampsia[J]. International Journal of Molecular Sciences, 2023, 24(16): 12743.
[25] Song Y X, He L P, Li C P. The relationship between serum calcium level and risk factor of pregnancy-induced hypertension: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2023, 50(3): 66.
[26] Lanssens D, Vandenberk T, Storms V, et al. Changes in Intrapersonal Factors of Participants in the Pregnancy Remote Monitoring Study Who Are at Risk for Pregnancy-Induced Hypertension: Descriptive Quantitative Study[J]. Journal of Medical Internet Research, 2023, 25: e42686.
[27] MM K C, Huo H, MM H H, et al. Cardiovascular Health Index Scores and Pregnancy-Induced Hypertension: An Association Study[J]. Alternative Therapies in Health and Medicine, 2023, 29(5): 141-145.
[28] Yu Lei, Wang Xia, Zhang Caixia. Clinical study of nifedipine sustained-release tablets combined with magnesium sulfate injection in the treatment of patients with pregnancy-induced hypertension [J]. Chinese Journal of Clinical Pharmacology, 2020, 36(11):1460-1463.
[29] Ma Xiaolian, Zheng Deyou, He Jiqing. Clinical study of nimodipine tablets combined with magnesium sulfate injection in the treatment of pregnancy-induced hypertension [J]. Chinese Journal of Clinical Pharmacology, 2019, 35(19):2243-2245, 2264.
[30] Zheng Qi, Wu Xiaoqing, Wang Bo, et al. Effect of quantitative assessment-guided process nursing model on pregnancy outcomes in patients with gestational hypertension [J]. China Medical Herald, 19(36): 174-177.
[31] Yan Lingling, Huang Yanfang. Observation on the efficacy of levamlodipine besylate tablets combined with phentolamine in the treatment of pregnancy-induced hypertension [J]. Medical Clinical Research, 2019(11):2211-2213.

Downloads: 456
Visits: 14645

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.